Signals, Powered By EquityPandit
Brazil’s federal government on Tuesday nationally suspended the vaccination of pregnant women with the AstraZeneca COVID-19 vaccine shot, after an expectant mother in Rio de Janeiro died from a stroke possibly related to the inoculation. Franciele Francinato, the coordinator of the Health Ministry’s vaccination program, told reporters the suspension was enacted as a precautionary measure after health regulator Anvisa issued a warning about the vaccine’s use in pregnant women earlier in the day. Authorities are investigating the incident. The suspension applies only to AstraZeneca’s shot and not to vaccines developed by Sinovac and Pfizer Inc that are also being used in the country.
The pregnant woman in Rio de Janeiro died after receiving the AstraZeneca shot, according to state Health Secretary Alexandre Chieppe. Anvisa said the 35-year-old woman, who was 23 weeks pregnant, died of a hemorrhagic stroke on Monday after checking into a hospital five days earlier. “The serious adverse event of a hemorrhagic stroke was assessed as possibly related to the use of the vaccine given to the pregnant woman,” Anvisa said in a statement.
- Just Dial Stocks Skyrocketed 15% On Announcement of Q4FY24 Business and Financial Updates
- Swing-Trading 101: Capturing Market Moves with Flexibility
- Jubilant Pharmova Shares Climbed 8% On Announcing Ceastion of Loss Making Arm’s Operations in Salisbury, USA
- Paytm Shares Gained 4.5% on NPCL’s Approval To Create New VPAs with Axis, HDFC, SBI, and Yes Bank
- Ambuja Cements Shares Gained 3% On Receiving Additional Rs 8,339 Crore Investment From Adani Group
AstraZeneca said in a statement that pregnant women and those breastfeeding were excluded from clinical trials of its COVID-19 vaccine. Studies in animals did not produce direct or indirect evidence of harm regarding pregnancy or fetal development, the statement added. Anvisa said it had not been informed of any other adverse events in pregnant women receiving the vaccine. The AstraZeneca vaccine is produced and distributed in Brazil via a partnership with the public health institute Fiocruz.
